PCN197 - COST UTILITY ANALYSIS OF FIRST-LINE PACLITAXEL WITH CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB VERSUS PEMETREXED WITH CARBOPLATIN FOLLOWED BY MAINTENANCE PEMETREXED IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER IN LEBANON

Publication | Open Access

DOI Full Paper Access

Citations

References

2018

Year

Arafat Tfayli, Fernando Melhem Elias, Fadi Farhat, R. Slim, Z. Hallal, Layal Maatouk, Aseel I. Ibrahim, Intissar Anan

Value in Health